Retatrutide vs Semaglutide: the triple agonist against the original

These two sit at opposite ends of the incretin class. Semaglutide activates one receptor, GLP-1, and built the entire market. Retatrutide activates three, GLP-1 plus GIP plus glucagon, and holds the largest published weight-loss figure in the class. Between the two molecules sits nearly a decade of pharmacology and, in the Philippines, a completely different buying reality.

Semaglutide is pure GLP-1 receptor agonism: satiety signaling to the brain, slower gastric emptying, improved insulin response. The weight loss is driven almost entirely by eating less. It is the cleanest, most-studied version of the incretin mechanism, which is both its strength and its ceiling.

Retatrutide keeps that GLP-1 base, adds GIP, and then adds the glucagon receptor. Chronically pulsed glucagon activation drives hepatic fat oxidation and raises resting energy expenditure, shifting the body toward burning stored fat even at rest. That third receptor is the mechanistic explanation for the size of the gap in the trial numbers, and it is also why retatrutide shows up in liver-fat research, covered in my retatrutide liver research filing.

The published anchors: retatrutide 12mg averaged 28.3% body-weight loss at 80 weeks in Phase 3 TRIUMPH-1 (Jastreboff et al., NEJM 2023); semaglutide 2.4mg averaged 14.9% at 68 weeks in STEP 1 (NEJM 2021). For a 90kg person those averages translate to roughly 22kg versus 13kg. No single trial has run them head-to-head, so treat the comparison as two strong data points rather than one controlled answer.

Context from the rest of the class sharpens the picture: tirzepatide, the two-receptor middle step, posted 22.5% in SURMOUNT-1 and beat semaglutide by roughly 8 percentage points in the head-to-head SURMOUNT-5. Each added receptor has, so far, moved the number in the same direction. Retatrutide's Phase 3 TRIUMPH results are the test of whether the pattern holds at scale.

Both compounds produce the class-standard gastrointestinal effects, nausea first among them, concentrated in dose-escalation weeks. Retatrutide's titration is generally reported as the more intense of the two, and its trial data shows small heart rate increases that semaglutide's does not. Semaglutide's profile is the best-mapped in the class simply because more people have taken it for longer.

Pharmacy figures were read from the chains' own listings and checked on 26 August 2026. Each branded pen holds four weekly doses, so one pen is roughly one month. The asymmetry is the story: semaglutide is the only one of the two you can buy at a counter, and the pen route costs roughly two to four times the research-grade route for the same molecule, not the four to six times this page used to claim against inflated pen prices. Retatrutide pricing exists only in the research market. Full channel detail sits in the Ozempic price filing and the peptide price index.

The common Philippines pattern is semaglutide first, then an upgrade after plateau. The documented protocol shape: finish the final semaglutide dose on schedule, wait 7 days, start retatrutide at 2mg weekly, titrate up gradually. The glucagon receptor is a genuinely new stressor for a body adapted to GLP-1 monotherapy, and everyone who rushes the ramp reports the same escalation-week misery. Going the other direction, retatrutide to semaglutide, is rarer and simpler: same 7-day washout, then standard semaglutide titration.